Metabolic Risk Stratification in Hospital Practices 1

A review and business-model analysis for value-based hospital growth

Abstract

 Diagnosis-related group and diagnosis-intervention packet (DRG/DIP) programs, centralized procurement of drugs and consumables, and tightening fiscal support are compressing the traditional revenue model of hospitals, which has long depended on test volume, drug turnover, consumable use, and bed occupancy. At the same time, most developed countries carry the world's largest burden of metabolic disease: roughly million adults with diabetes and a still larger population with prediabetes, obesity, and fatty liver disease. Insulin resistance sits upstream of nearly all of these conditions and, increasingly, of two further outcomes hospitals have not traditionally organized around: several common cancers and, as this review adds to the discussion, Alzheimer's disease. This paper synthesizes the epidemiological and mechanistic evidence linking insulin resistance to metabolic disease, oncogenesis, and neurodegeneration; reviews the recent, clinically consequential advances in blood-based biomarkers that make population-relevant Alzheimer's disease risk assessment newly feasible; health-management-oriented hospital service line — a Metabolic and Neuro-Metabolic Function Assessment Center — built around insulin-resistance evaluation, tiered laboratory testing, multidisciplinary lifestyle intervention, and long-term follow-up. The model is designed to generate durable, non-insurance revenue while remaining strictly within evidentiary and regulatory bounds: it does not diagnose cancer or Alzheimer's disease, and it does not promise to prevent either. Its value lies in identifying modifiable risk earlier, in a population that would otherwise not be assessed until disease is already symptomatic.

1. Introduction: Hospitals at an Inflection Point

Hospitals are moving from an era in which revenue scaled with volume — more imaging studies, more medication, more consumables, more inpatient days — to one in which revenue depends on cost discipline, standardized clinical pathways, and the efficient use of a fixed, per-case payment. This shift is not cosmetic. It changes what counts as a viable service line. A department that generates a surplus under fee-for-service can generate a deficit under a bundled DRG or DIP payment if its case mix skews toward complex, resource-intensive patients or if its length of stay and consumable use are not tightly managed. For a new service line to be strategically sound in this environment, it should meet four conditions: the addressable population must be large enough to sustain volume; the underlying condition must carry enough long-term disease burden to justify ongoing management rather than a single encounter; the intervention pathway must be standardizable and reproducible across clinicians; and the revenue must not depend primarily on insurance reimbursement, since insurance-funded pathways are precisely the ones now being compressed by payment reform. Metabolic disease management, organized around insulin resistance as a common upstream mechanism, satisfies all four conditions more clearly than most alternatives currently being proposed inside hospitals. This review makes three contributions beyond the strategy memoranda already circulating in hospital management circles. First, it separates the parts of the insulin-resistance narrative that are well supported by peer-reviewed evidence from the parts that are not, since several widely repeated figures including specific numeric claims about cancer risk multipliers — could not be traced to a verifiable primary source and should not be used in a publication-ready document. Second, it extends the metabolic-risk framework to a domain not covered in this review is based on: Alzheimer's disease, where insulin resistance is mechanistically implicated and where blood-based screening biomarkers have matured rapidly since 2024. Third, it reframes the proposed hospital business model accordingly, adding a neuro-metabolic risk tier while keeping the compliance guardrails that any responsible version of this model requires.

2. The Structural Pressures Reshaping Hospital Economics

 2.1 Payment reform: DRG and DIP

 AS China's National Healthcare Security Administration began piloting Diagnosis-Related Group (DRG) payment in 30 cities and Diagnosis-Intervention Packet (DIP) payment in 71 cities in 2019 and 2020, and by the end of 2024 roughly 70 percent of insurance-funded inpatient costs nationwide were paid through one of the two mechanisms, with full rollout to all qualifying institutions targeted for the end of 2025. Under DIP in particular, hospitals are paid a fixed amount per disease-and-treatment combination rather than for each service rendered, which directly rewards shorter stays, lower drug and consumable intensity, and standardized clinical pathways, and directly penalizes the older habit of generating revenue through test and medication volume. Evaluations of DIP implementation in pilot cities such as Guangzhou have documented exactly this shift: falling per-case drug and consumable expenditure alongside continued or improved quality indicators, but also a compression of the margin hospitals can extract from any single inpatient episode.

2.2 Public hospital financial strain

 The financial consequences of this transition, layered on top of years of aggressive capital expansion, have become visible in business press rather than only in policy literature. Caixin reported in 2025 that public hospitals across multiple provinces were carrying mounting debt, and patient outflow toward top-tier centers, and constrained government subsidy. This review deliberately does not repeat the specific loss-rate percentages that circulate in some hospital strategy memoranda — figures such as a particular share of tertiary public hospitals operating at a loss in a given quarter — because those figures could not be traced to a verifiable primary source (the National Health Commission, a provincial health authority, or a peer-reviewed operations study) during the preparation of this review. The qualitative direction of the evidence, however, is consistent and well documented: total national health expenditure rose from roughly 5.91 trillion yuan in 2018 to 9.06 trillion yuan in 2023, a compound growth rate of about 9 percent per year, a pace of expenditure growth that payment reform is explicitly designed to slow.

 2.3 Private tertiary hospitals: a more concentrated exposure

Large private tertiary hospitals face a version of this pressure that is structurally more acute. Heavy up-front capital investment translates into high depreciation and financing costs that must be serviced regardless of case volume; under-utilized bed capacity cannot easily be shed; DIP-style payment compresses the margin on any individual surgical or inpatient case; and brand trust, which drives referral volume in hospital market, takes years to build. A private hospital that continues to rely primarily on inpatient and procedural revenue under these conditions has limited room to grow. The logical response is to develop asset-light, high-repeat-visit, adherence-dependent, standardizable service lines that do not depend on insurance reimbursement — which is precisely the profile of a well-run chronic metabolic risk management service.

2.4 Policy direction: from volume to value

Current policy language consistently favors capability-building, chronic disease management, multidisciplinary collaboration, extension into health management services, data-driven operational optimization, and compliant expansion of specialty and health-management services, over the older pattern of expanding beds, imaging volume, and drug revenue. This creates policy space, though not policy certainty, for hospitals to develop metabolic-disease business lines organized around early risk assessment and long-term management rather than acute treatment alone.

3. The Metabolic Disease Burden and Insulin Resistance as a Common Upstream Driver

 3.1 Scale of the problem

According to the International Diabetes Federation's 2024 country estimate, China has approximately 148 million adults aged 20 to 79 living with diabetes, a prevalence of roughly 11.9 percent of the adult population, with the number projected to remain the world's highest through at least 2050. Prediabetes prevalence is substantially higher still: the IDF's 2024 update, published in Diabetes Care, put the global prevalence of impaired glucose tolerance at 12.0 percent (up from 9.1 percent in the 2021 estimate) with China contributing a large share of the absolute case count given its population size. Regional cross-sectional studies of nonalcoholic fatty liver disease (NAFLD) in Chinese adults, such as a 2023 study of more than 110,000 individuals in Chongqing, have found prevalence around 28 to 29 percent in the general adult population, rising far higher among individuals who are overweight or obese, consistent with the broader literature identifying NAFLD as one of the most common chronic conditions in urban Chinese adults. Hypertension, dyslipidemia, hyperuricemia, obesity, and polycystic ovary syndrome add further, overlapping strata to this population. The operationally important point for hospital strategy is not any single prevalence figure but the fact that these conditions cluster in the same individuals, that the large majority of people carrying this risk have not been systematically evaluated or enrolled in structured long-term management, and that most of this population is currently outside any hospital's active management pathway — they appear, if at all, as an incidental finding on an annual health check, not as a patient in a structured program.

 3.2 Insulin resistance as a unifying pathophysiology

Insulin resistance — a reduced biological response to a given level of circulating insulin, most often assessed clinically through the Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) or, more conveniently in large-scale or lower-resource settings, the triglyceride-glucose (TyG) index calculated from fasting triglycerides and glucose — is not simply an early marker of type 2 diabetes. It disrupts glucose and lipid metabolism, energy storage, systemic inflammation, vascular function, and hormonal signaling simultaneously, and it sits mechanistically upstream of type 2 diabetes and prediabetes, obesity and especially central adiposity, nonalcoholic fatty liver disease, dyslipidemia, hypertension, hyperuricemia, polycystic ovary syndrome, and an elevated background risk for atherosclerotic cardiovascular disease. Because a single, inexpensive laboratory assessment captures risk that would otherwise require separately diagnosing and separately managing each downstream condition, insulin-resistance evaluation is a natural organizing principle for a hospital service line that spans endocrinology, cardiology, hepatology, gynecology, nutrition, and rehabilitation medicine rather than sitting inside any one department.

4. Insulin Resistance and Cancer Risk: What the Evidence Actually Shows

 The relationship between insulin resistance and cancer risk is real, biologically plausible, and supported by a substantial and growing observational literature, but it is more modest and more heterogeneous across cancer types than some strategy literature suggests, and it should be presented to patients and regulators with corresponding caution. Mechanistically, chronic hyperinsulinemia is thought to promote carcinogenesis through several overlapping pathways: direct mitogenic signaling through the insulin and insulin-like growth factor-1 (IGF-1) receptors, which are structurally related and can cross-activate; suppression of sex-hormone-binding globulin, which increases the bioavailability of circulating sex steroids relevant to hormone-sensitive cancers such as breast cancer; chronic low-grade inflammation; and altered adipokine secretion from expanded, dysfunctional adipose tissue. These mechanisms are reasonably well established at the cell-biology level. At the population level, the TyG index — used as a practical, low-cost proxy for insulin resistance — has been associated with cancer risk across multiple independent meta-analyses. A 2023 meta-analysis in Frontiers in Endocrinology found a significant association between elevated TyG index and cancer risk overall, while a large Norwegian, Austrian, and Swedish cohort study of obesity-related cancers found that higher TyG index predicted increased risk of several obesity-related cancer types independent of body-mass index. A 2025 prospective cohort study similarly found the TyG index to be an independent predictor of incident cancer over follow-up. However, the relationship is not uniform: a 2025 systematic review found consistent positive associations for several digestive and genitourinary cancers but a paradoxical inverse association for esophageal squamous cell carcinoma in at least one study, and a 2025 meta-analysis specific to breast cancer found that case-control and cross-sectional studies showed a positive association while prospective cohort studies did not reach statistical significance — a pattern that is itself informative, since prospective cohort designs are generally less susceptible to reverse-causation bias than case-control designs comparing already-diagnosed patients with healthy controls. The honest summary for a hospital-facing document is therefore: insulin resistance is a biologically plausible and observationally supported contributor to elevated cancer risk across several cancer types, of a magnitude and consistency that justifies including it as one factor within a broader risk-stratification and lifestyle-intervention program, but it is not established as an independent diagnostic or predictive tool for any specific cancer, the size of the association varies considerably by cancer type and study design, and specific numeric claims — such as a fixed percentage increase in risk, or a fixed number of cancer types for which insulin resistance is an independent risk factor — should not be asserted without citing the specific primary study, population, and adjusted effect size, none of which support a single universal figure at present.

5. The New Frontier: Insulin Resistance, Hyperinsulinemia, and Alzheimer's Disease

 5.1 The "type 3 diabetes" hypothesis

The idea that Alzheimer’s disease shares core pathophysiology with diabetes is not new: the phrase "type 3 diabetes" was proposed in the mid-2000s to describe the observation that the brain, like the liver and skeletal muscle, is an insulin-responsive organ, and that impaired insulin signaling in neurons produces effects — reduced glucose uptake, disrupted synaptic plasticity, altered processing of amyloid precursor protein, and abnormal tau phosphorylation — that parallel the pathology seen in Alzheimer’s disease. A widely cited 2008 review by de la Monte and Wands laid out this argument in detail, and subsequent epidemiological work has generally supported the underlying association even as the field has moved away from treating Alzheimer’s disease as literally a form of diabetes.

 5.2 Mechanistic pathways: brain insulin resistance, amyloid, and tau

 Type 2 diabetes and insulin resistance appear to promote Alzheimer's-type pathology in animal models, and in humans, elevated HOMA-IR has been associated with an Alzheimer's-like pattern of reduced cerebral glucose metabolism in frontal, parietotemporal, and cingulate brain regions, independent of age, oral glucose tolerance, or APOE ε4 carrier status, according to imaging studies reviewed by Kim and Feldman in a widely cited 2015 mechanistic review. Proposed pathways include disruption of the blood-brain barrier by dyslipidemia and elevated free fatty acids, activation of microglia and astrocytes with resulting chronic low-grade brain inflammation, direct induction of neuronal insulin resistance by amyloid-beta oligomers, and impaired clearance of amyloid-beta, which is normally degraded in part by insulin-degrading enzyme — an enzyme that becomes preferentially occupied with degrading insulin under conditions of chronic hyperinsulinemia, potentially leaving more amyloid-beta unprocessed. A 2024 review in Biomedicines by Affuso and colleagues summarizes this literature and explicitly notes that peripheral insulin resistance is a documented, independent risk factor not only for type 2 diabetes and cardiovascular disease but for cognitive decline and cellular senescence as well.

 5.3 Epidemiological evidence in humans

 Clinical studies in cognitively normal middle-aged adults have found that higher HOMA-IR is associated with worse performance on specific cognitive domains and with elevated cerebrospinal fluid tau, a core Alzheimer's disease biomarker, years before any clinical diagnosis would be made. A large 2013 meta-analysis found that individuals with type 2 diabetes carried a 73 percent higher risk of all-cause dementia, a 56 percent higher risk of Alzheimer's disease specifically, and a 127 percent higher risk of vascular dementia compared with individuals without diabetes. It is important to note that the relationship is not identical for every form of cognitive decline: at least one large study found that elevated HOMA-IR was a strong, independent predictor of progression to the small-vessel, vascular subtype of dementia but not specifically of Alzheimer's disease once that comparison was isolated — a distinction any clinically responsible program needs to communicate, since insulin resistance appears to raise risk across the broader dementia spectrum with a mechanism and strength of association that differs somewhat by dementia subtype. The population relevance of this connection for China is substantial. China has the largest number of people living with dementia of any country: a widely cited 2013 Lancet analysis estimated 9.19 million dementia cases nationally as of 2010, of which 5.69 million were attributed to Alzheimer's disease specifically, and more recent nationally representative surveys, including a 2020 study in The Lancet Public Health covering more than 46,000 adults aged 60 and older across 12 provinces, have confirmed that dementia and mild cognitive impairment remain substantially underdiagnosed and undermanaged in routine clinical practice. A population already being evaluated for metabolic risk in a hospital's insulin-resistance program is, by definition, a population at elevated background risk for this outcome as well.

 6. Screening for Prediction: Blood-Based Biomarkers for Alzheimer's Disease Risk

 The single largest change in Alzheimer's disease risk assessment since 2024 — and the reason this review adds a dedicated section not present in the original strategy document — is the maturation of blood-based biomarkers that can detect Alzheimer's-related brain pathology years before clinical symptoms, using a standard venous blood draw rather than a lumbar puncture or PET scan.

To be continued

支持单位：